Navigation Links
GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial
Date:9/24/2007

ATLANTA, Sept. 24 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX)

On September 21, 2007, Merck & Co., Inc. announced their candidate AIDS vaccine failed to provide protection in a human study designed to test for efficacy.

In this Merck trial involving high risk volunteers, an equal number of people received either placebo or AIDS vaccine. The independent Data Safety Monitoring Board recommended that the trial be stopped because it was not reaching its efficacy endpoints.

Merck has stopped further vaccinations but will continue to follow volunteers in the trial. The Merck trial was being carried out in conjunction with the HIV Vaccine Trials Network (HVTN), a prestigious trial network funded by the US National Institutes of Health.

Don Hildebrand, GeoVax's President and CEO, commented, "We, along with the rest of the scientific community, are disappointed in the clinical failure of Merck's HIV vaccine trial. We all share the same goal of finding a safe and effective vaccine to address the devastation of the HIV/AIDS epidemic. We, however, would like to take this opportunity to highlight important differences between our vaccine technology and the technology used in the Merck trial."

GeoVax AIDS vaccines advancing in human trials represent a significantly different vaccine approach, vaccine composition and results to date than the Merck vaccine.

1) Prototypes for the GeoVax vaccines were selected from a series of trials in non-human primates for their ability to protect against the development of AIDS when vaccinated individuals were administered an AIDS causing virus. At each major step along the development pathway, GeoVax vaccines providing the best protection against AIDS were moved forward.

2) GeoVax AIDS vaccines demonstrated excellent protective results in non- human primate models, much better protective results than reported for Merck's vaccine in similar models. GeoVax AIDS vaccines pro
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Officer, will present at the Stem Cell Meeting on ... 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... 2014 Arbor Pharmaceuticals, LLC. - Product ... Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product Pipeline ... Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Arbor Pharmaceuticals, LLC.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... Sept. 30, 2014  According to their CEO, ... cancer clinical trials is going through a complete ... the work of the current clinical trial management ... ,next generation, clinical trials, which will ultimately drive ... The company has been recognized by the ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Today GenVec, Inc. (Nasdaq: GNVC ) announced financial ... 2010.  For the year ended December 31, 2010, the Company ... share, compared with a net loss of $18.4 million, or ... GenVec ended the year with $35.2 million in cash, cash ...
... RIVER EDGE, N.J., March 10, 2011 Nephros, Inc. ... device company developing and marketing filtration products for therapeutic ... completion of its rights offering and private placement that ... to Nephros.  The aggregate net proceeds received by Nephros ...
Cached Medicine Technology:GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 2GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 3GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 4GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 5GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 6GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 7GenVec Reports Fourth Quarter and 2010 Year-End Financial Results 8Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 2Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 3Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 4
(Date:10/1/2014)... for holiday gift ideas? Éminence Organic Skin Care, the leader ... holiday season. Starting October 1st 2014, new spa gift sets ... Choose from two luxury skin care gift sets made from ... or to deliver whole body beauty. , The luxurious ... are formulated to suit all skin types and will tick ...
(Date:10/1/2014)... October 01, 2014 QueenBeeTickets.com is giving music ... the singer’s upcoming North American tour, which has him traveling ... come. , Click here to view the selection ... performer’s newest album, is due to come out on October ... shortly thereafter. Bob Seger concert tickets are available for shows ...
(Date:9/30/2014)... no genetic evidence that high levels of vitamin D ... Some previous research had suggested that elevated levels ... diabetes, raising the possibility of a link between vitamin ... this study, British researchers investigated the association between diabetes ... control blood levels of vitamin D. They found no ...
(Date:9/30/2014)... damaging "brain tsunamis" in injured patients without opening ... reality, thanks to pioneering research at the University ... team, led by Jed Hartings, PhD, research associate ... UC College of Medicine, has shown that spreading ... like tsunami wavescan be measured by the placement ...
(Date:9/30/2014)... Symposia will convene the first conference of its 2014-2015 ... Series on "The Modes of Action of Vaccine ... the conclusion of the Grand Challenges Meeting for that ... Keystone Symposia Global Health Series, supported by the Bill ... awards for 36 investigators from developing countries to attend. ...
Breaking Medicine News(10 mins):Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:Bob Seger Presale Tickets: QueenBeeTickets.com Delights Fans with Discounted Tickets for All 20 Stops on Seger’s “Ride Out” Tour with The Silver Bullet Band 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2
... neck pain by spine manipulation appears of little use as ... in the UK to relieve many different types of pain,// ... ,When 16 studies were reviewed it was concluded ... is effective for treating any medical problem. ...
... member of the parliament belonging to the Papua New Guinea parliament ... virus//. He will be the first person in the country to ... unnamed MP could be jailed under a 2003 law that made ... Nation newspaper in Papua New Guinea reported. ,The paper ...
... became known that they had cheated the Medicare by more ... were not mandated and hence was never conducted. ... of the illegal scheme from 1997 to 2005. He and ... beneficiaries and introducing them to several doctor’s and medical labs ...
... (FSA), that the daily intake of salt should be limited to ... mention the amount of salt content in their food labels. A ... either side. ,A public awareness watchdog for Foodstuffs set ... salt in a lot of food products. This is done for ...
... common man that how official failings led to a man ... history of violence. Stuart Robertson was killed by James Smith, ... in October 2004. This report mainly gives us an insight ... , There was a failure to respond adequately ...
... the first of its kinds study conducted by the ... Communications Research (CECCR) found// that Women suffering from breast ... given the opportunity to participate in online support groups. ... to ,openly express themselves trying to make sense of ...
Cached Medicine News:Health News:Research demystifies treatment by manipulation of spine by chiropractors in the UK 2Health News:Salt & Its Intake Causes a Strong debate In UK 2Health News:Study Finds Online Support Groups Emotionally Benefit Women Suffering From 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: